MS drug LEMTRADA under pregnancy microscope: what are the risks?
NCT ID NCT03774914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tracked 42 women with multiple sclerosis who became pregnant around the time they received LEMTRADA infusions. Researchers aimed to measure rates of miscarriage and birth defects to better understand the drug's safety during pregnancy. The study did not test a new treatment but gathered real-world data to guide future medical advice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alemtuzumab (Lemtrada)
What this could lead to
If successful, this study could provide clearer safety data on LEMTRADA use during pregnancy, helping women with MS make informed family-planning decisions.
What could go wrong
This is an observational registry with only 42 participants, so results may not apply broadly. It does not test a new treatment, only monitors existing drug exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 036001
Box Hill, Victoria, 3128, Australia
-
Investigational Site Number : 040-001
Linz, Austria
-
Investigational Site Number : 124999
Canada, Canada
-
Investigational Site Number : 208001
Aarhus C, 8000, Denmark
-
Investigational Site Number : 276001
Bochum, 44791, Germany
-
Investigational Site Number : 380001
Gallarate (VA), 21013, Italy
-
Investigational Site Number : 528999
Netherlands, Netherlands
-
Investigational Site Number : 56
Charleroi, 6000, Belgium
-
Investigational Site Number : 724999
Spain, Spain
-
Investigational Site Number : 752001
Gothenburg, 41345, Sweden
-
Investigational Site Number : 826-001
Salford, M6 8HD, United Kingdom
-
Site Number : 840999
New York, New York, United States